Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
The structure of LO is divided in two domains the
2024-09-03

The structure of 5-LO is divided in two domains, the catalytic C-terminal domain and the N-terminal regulatory C2-like domain (C2ld) [59,60]. The C2ld spans the flumethasone 1-114 and is responsible for translocation and binding of calcium and membranes [61–63]. The catalytic domain is primarily an
-
As we previously observed in the
2024-09-03

As we previously observed in the NSFT (Fukumoto et al., 2014), the effect of LY341495 in the FST was also inhibited by a 5-HT1A receptor antagonist, indicating the role of the 5-HT1A receptor in the actions of LY341495. Among the 5-HT1A receptors, which exist both presynaptically and postsynapticall
-
br Experimental procedures br Results br Discussion
2024-09-03

Experimental procedures Results Discussion Although previous studies have indicated that astrocyte aromatase plays a role in nociceptive processes (O'Brien et al., 2015, Smeester et al., 2016), the mechanisms responsible for the regulation of aromatase and its involvement in nociception rem
-
Available data thus indicate that
2024-09-02

Available data thus indicate that there are at least two ways that HMGA proteins can induce localized changes in the chromatin structure of inducible gene promoters, both of which involve positioned nucleosomes that must be “remodeled” before gene transcription can occur. The first mechanism is exem
-
Expression of Twist and the
2024-09-02

Expression of Twist1 and the AR are increased by oxidative stress, but the change in the receptor (mRNA/protein) is lost after treatment with siRNAs that target Twist 1 (Shiota et al., 2010). Twist 1 was found to bind to E-boxes, 5′-CANNTG-3′, in the proximal promoter (−442 to +51 bp) and upstream r
-
AR Vs are truncated AR proteins lacking
2024-09-02

AR-Vs are truncated AR proteins lacking the AR ligand-binding domain (AR-LBD) [6]. While AR-Vs have frequently been detected in CRPC, their expression and functional role in benign prostate tissues and primary prostate cancers is not readily apparent. Structural rearrangements in the AR gene and alt
-
Recently Kamoshita et al evaluated a mouse model of
2024-09-02

Recently, Kamoshita et al. (2016) evaluated a mouse model of retinal neuronal disturbance with the intraperitoneal injection of LPS and found that treatment with AICAR suppressed the reduction of conical function and decreased mRNA levels of TNF-α as well as improved mRNA levels of the mitochondrial
-
Neural activity resulting from sensory experience is require
2024-09-02

Neural activity resulting from sensory experience is required for the refinement and maturation of neural circuits during cortical critical periods. This refinement is thought to be important for functional optimization of primary sensory cortices, enabling critical functions such as feature detecti
-
In this study we designed and synthesized two ALK
2024-09-02

In this study, we designed and synthesized two ALK PROTACs (degraders), 5 (MS4077) and 6 (MS4078), by linking ceritinib and pomalidomide [45] through two different linkers. Using human ALCL and NSCLC cells, we characterized both compounds in a battery of assays to demonstrate their effects on reduci
-
HT receptors are distributed throughout the brain within the
2024-08-31

5-HT3 receptors are distributed throughout the brain, within the brainstem (e.g., nucleus tractus solitarius, area postrema and spinal trigeminal nucleus) and Anhydrotetracycline hydrochloride (e.g., hippocampus, amygdala, nucleus accumbens, putamen and caudate) (Abi-Dargham et al., 1993, Barnes et
-
Beside activation of adenosine receptors
2024-08-31

Beside activation of adenosine receptors (A2a.1, A2a.2, A2b) by FSK treatment, the expression of adenosine receptors was also upregulated, when embryos were exposed to inhibitors (SU5416 and DAPT) alone and also combined with FSK. Our data imply that adenosine receptor was associated with a positive
-
sVRPs were more sensitive to ABT than
2024-08-31

sVRPs were more sensitive to ABT-702 than MSRs. This result agrees with previous reports that the activation of A1 receptors more potently inhibits sVRPs than MSRs (Nakamura et al., 1997, Otsuguro et al., 2009). Importantly, sVRPs are thought to reflex C-fiber-evoked nociceptive transmission. Nocice
-
Our second patient years old
2024-08-31

Our second patient, 42years old male, a farmer, was all right when he went to sleep, but noticed drooping of eyelids and swallowing difficulty when he woke up. He later developed flaccid weakness of all four limbs and was quadriplegic when he was wheeled into the emergency room. He was tachypneic an
-
An AXL decoy receptor with enhanced GAS
2024-08-31

An AXL decoy receptor with enhanced GAS6-binding properties, MYD1, was engineered as a therapeutic tool to disrupt GAS6/AXL signaling in vivo (Kariolis et al., 2014). MYD1 was shown to block metastasis of human ovarian cancer guggulsterone and a murine breast cancer cell line in grafting assays in
-
Over the past decade extensive research has been
2024-08-31

Over the past decade, extensive research has been directed toward the discovery of Aurora-selective small-molecule inhibitors. As a result, a handful of Aurora inhibitors has been identified. Among them, 1 (VX-680) and 2 (SNS-314) have entered human clinical trials as pan-Aurora kinase inhibitors (F
16403 records 107/1094 page Previous Next First page 上5页 106107108109110 下5页 Last page